Cramer Pans the Artes Medical IPO, Says Too Speculative

Photo of Douglas A. McIntyre
By Douglas A. McIntyre Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

On tonight’s MAD MONEY, Cramer featured the IPO frenzy with 2 positive and 1 negative.  He already reviewed IPGP and GUID as very positive IPO’s, but he actually panned ARTE and said it is far too speculative to buy.

Artes Medical (ARTE): This is an antiwrinkle company that he really likes and said it was designed to get his blessing.  He said this would have been called a bad company in the old days, but he thinks it is too speculative to merit a buy.  The FDA won’t allow it to be marketed as a permanent solution, and they only have 1 product.  This could be deemed unsafe by doctors and it could be sued.  It needs cash, and Cramer doesn’t like the need for cash and the burn rates.  No earnings, no sales, could be abused by Allergan and others……You get the picture, he doesn’t like it.

I will predict that the company asks to come on his show shortly after coming public, assuming that the Cramer pan didn’t just result in the IPO being pulled.  This IPO-featuring on a pre-pricing basis just doesn’t seem right.

Jon C. Ogg
December 12, 2006

Photo of Douglas A. McIntyre
About the Author Douglas A. McIntyre →

Douglas A. McIntyre is the co-founder, chief executive officer and editor in chief of 24/7 Wall St. and 24/7 Tempo. He has held these jobs since 2006.

McIntyre has written thousands of articles for 24/7 Wall St. He is an expert on corporate finance, the automotive industry, media companies and international finance. He has edited articles on national demographics, sports, personal income and travel.

His work has been quoted or mentioned in The New York Times, The Wall Street Journal, Los Angeles Times, The Washington Post, NBC News, Time, The New Yorker, HuffPost USA Today, Business Insider, Yahoo, AOL, MarketWatch, The Atlantic, Bloomberg, New York Post, Chicago Tribune, Forbes, The Guardian and many other major publications. McIntyre has been a guest on CNBC, the BBC and television and radio stations across the country.

A magna cum laude graduate of Harvard College, McIntyre also was president of The Harvard Advocate. Founded in 1866, the Advocate is the oldest college publication in the United States.

TheStreet.com, Comps.com and Edgar Online are some of the public companies for which McIntyre served on the board of directors. He was a Vicinity Corporation board member when the company was sold to Microsoft in 2002. He served on the audit committees of some of these companies.

McIntyre has been the CEO of FutureSource, a provider of trading terminals and news to commodities and futures traders. He was president of Switchboard, the online phone directory company. He served as chairman and CEO of On2 Technologies, the video compression company that provided video compression software for Adobe’s Flash. Google bought On2 in 2009.

Continue Reading

Top Gaining Stocks

AKAM Vol: 21,556,944
MU Vol: 65,135,624
INTC Vol: 227,504,426
MNST Vol: 15,284,847
DELL Vol: 12,167,525

Top Losing Stocks

MSI Vol: 3,101,643
EXPE Vol: 4,189,786
CTRA Vol: 73,319,495